Discovery Stage Partnering Agreements in Biopharma

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in discovery stage dealmaking

• 2.1. Introduction
• 2.2. Difference between discovery technologies and discovery compound deals
  • 2.2.1. Trends in discovery stage deals since 2000
  • 2.2.2. Attributes of discovery stage deals
• 2.3. Reasons for entering into discovery stage partnering deals
  • 2.3.1. Licensors reasons for entering discovery stage deals
  • 2.3.2. Licensees reasons for entering discovery stage deals
• 2.4. Components of discovery stage deals
• 2.5. Therapeutic focus of discovery stage deals
  • 2.5.1. Oncology discovery dealmaking
  • 2.5.2. CNS discovery dealmaking
  • 2.5.3. Infectious discovery dealmaking
  • 2.5.4. Autoimmune/Inflammatory discovery dealmaking
• 2.6. Technology focus of discovery deals
• 2.7. The future of discovery stage partnering deals

Chapter 3 - Overview of discovery stage deal structure

• 3.1. Introduction
• 3.2. The anatomy of a discovery stage deal
  • 3.2.1. Example discovery stage agreements
    • 3.2.1.a. Case study 1: Celgene - Array Biopharma - September 2007
    • 3.2.1.b. Case study 2: GlaxoSmithKline - Targacept - July 2007
• 3.3. Typical discovery stage payment terms
  • 3.3.1. Headline deal values
  • 3.3.2. Upfront payments
  • 3.3.3. Milestone payments
  • 3.3.4. Royalties

Chapter 4 - Leading discovery stage deals

• 4.1. Introduction
• 4.2. Top discovery stage deals by value
• 4.3. Top discovery stage deals signed by bigpharma
• 4.4. Most active discovery stage dealmakers
• 4.5. Bigpharma discovery stage deal activity

Chapter 5 - Bigpharma discovery stage partnering agreements

• 7.1. Introduction
• 7.2. How to use discovery stage partnering agreements
• 7.3. Company discovery stage partnering agreement listings
• Abbott
• Actavis
• Alcon Labs
• Allergan
• Amgen
• Astellas
• AstraZeneca
• Barr Pharmaceuticals
• Baxter International
• Bayer
• Biogen Idec
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Chugai
• CSL
• Daiichi Sankyo
• Eisai
• Eli Lilly
• Forest Laboratories
• Genentech
• Genzyme
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• King
• Lundbeck
• Menarini
• Merck & Co
• Merck - Serono KGaA
• Mitsubishi
• Mundipharma
• Novartis AG
• Novo Nordisk
• Nycomed Pharma
• Otsuka
• Pfizer
• Procter & Gamble
• Ratiopharm
• Roche
• Sanofi-Aventis
• Schering Plough
• Servier
• Shire
• Solvay
• Stada
• Takeda
• Teva
• UCB
• Watson
• Wyeth

Chapter 6 - Discovery partnering agreement directory 2003-early 2008

• 6.1. Introduction
• 6.2. Company A-Z
• 6.3. By therapy area
• Accident/Hospital/Trauma
• Blood/Lymphatic System
• Cardiovascular
• Central nervous System
• Dermatology
• Gastrointestinal
• Genetic
• Genitourinary
• Autoimmune/Inflammatory
• Infection
• Metabolism
• Musculoskeletal
• Oncology
• Respiratory
• Sensory Organ / Oral Health
• Delivery
• 6.4. By deal type
• Collaborative R&D
• Co-development
• Co-marketing
• Co-promotion
• Development
• Distribution
• Joint venture
• Licensing
• M&A
• Manufacturing
• Marketing
• Promotion
• Research
• Supply

Appendices

• Appendix 1 - Discovery stage partnering references
• Appendix 2 - Resources
• Appendix 3 - Deal type definitions
• Appendix 3 - Deal type definitions
• Appendix 4 - Example discovery stage partnering contract
• About CurrentPartnering
• Recent report titles from CurrentPartnering
• Order Form - Reports
• Order form - Company Dealmaking Profiles

Table of figures

• Figure 1: Definition of discovery technology and discovery compound dealmaking
• Figure 2: Trends in discovery stage deal announcements, 2000-2007
• Figure 3: Frequency of deal components in discovery stage deals - 2003 to mid2008
• Figure 4: Discovery stage deals by therapy focus - 2003 - mid2008
• Figure 5: Frequency of oncology discovery dealmaking 2003-mid2008
• Figure 6: Primary discovery stage oncology dealmakers
• Figure 7: Frequency of CNS discovery dealmaking 2003-mid2008
• Figure 8: Primary discovery stage CNS dealmakers
• Figure 9: Frequency of infectious discovery dealmaking 2003-mid2008
• Figure 10: Primary discovery stage infectious dealmakers
• Figure 11: Frequency of autoimmune/inflammatory discovery dealmaking 2003-mid2008
• Figure 12: Primary discovery stage autoimmune/inflammatory dealmakers
• Figure 13: Technology focus for discovery deals 2003-mid2008
• Figure 14: Components of the discovery deal structure
• Figure 15: Discovery stage average payment terms
• Figure 16: Top discovery stage deals by value since 2003
• Figure 17: Bigpharma - top 50 - discovery stage deals since 2003
• Figure 18: Most active discovery stage dealmakers 2003-mid 2008
• Figure 19: Bigpharma - top 50 - discovery stage deals since 2003
• Figure 20: Online partnering resources
• Figure 21: Deal type definitions
• Figure 22: Partnering agreement between Dart Therapeutics and CombinatoRx - November 2007